Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Dauntless who wrote (5032)	8/1/1998 4:53:00 PM
From: Bill Wexler	Read Replies (3) \| Respond to of 7041

Zonagen management - thieves and hype artists When Zonagen management can't buy patents cheaply, they resort to theft in order to hype the stock price. Zonagen tried to patent an existing compound known as Chitosan and then failed to mention the rejection in their SEC filings. Don't be misled by the recent "news" of a "patent allowance" for their Immumax "system". This is another attempt to spin a worthless patent and mislead investors that Zonagen has something new, when in fact they haven't acquired any protection for any commercially viable product. Note that Zonagen has done this in the past with the Vasomax Patents - which were purchased for a song. TXB and ZONA were frauds that were spun out of Baylor College of Medicine. Zonagen started out as a company that was trying to develop Zona-pellucida based vaccines for the sterilization of animals. Unfortunately, since Zonagen has no R&D infrastructure, they were forced to steal research from a BCM scientist, Dr. Bonita Dunbar. Zonagen has never come up with an original idea, and has never generated an original patent. Everything about Zonagen is a facade that was either purchased, or stolen outright. Zonagen's price continues to collapse - and I continue to be 100% correct about the Zonagen fraud.